TCR signaling and environment affect vasoactive intestinal peptide receptor-1 (VPAC-1) expression in primary mouse CD4 T cells.

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Brain, behavior, and immunity

• Publication date

  2008-10-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.bbi.2008.04.005PMID 18534815PMCID PMC2771562
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Expression and fine mapping of murine vasoactive intestinal peptide receptor 1

  2007cited by this paper
• IL-2 induction by simian immunodeficiency virus involves MAP kinase signaling but is independent of calcineurin/NF-AT activity.

  2006cited by this paper
• The Role of Protein Kinase A Anchoring via the RIIα Regulatory Subunit in the Murine Immune System1

  2005cited by this paper
• Predominant expression of type II vasoactive intestinal peptide receptors by human T lymphoblastoma cells: Transduction of both Ca2+ and cyclic AMP signals

  2005cited by this paper
• Function of the Src-family kinases, Lck and Fyn, in T-cell development and activation

  2004cited by this paper
• The Significance of Vasoactive Intestinal Peptide in Immunomodulation

  2004cited by this paper
• The specificities of protein kinase inhibitors: an update.

  2003cited by this paper
• Regulation of T Cell Receptor CD3ζ Chain Expression byl-Arginine*

  2002cited by this paper
• Regulation of T cell receptor CD3zeta chain expression by L-arginine.

  2002cited by this paper
• Enhanced delayed-type hypersensitivity and diminished immediate-type hypersensitivity in mice lacking the inducible VPAC2 receptor for vasoactive intestinal peptide

  2001cited by this paper
• TH2 Lymphocytes Secrete Functional VIP upon Antigen Stimulation

  2001cited by this paper
• Selective Gene Expression and Activation-Dependent Regulation of Vasoactive Intestinal Peptide Receptor Type 1 and Type 2 in Human T Cells1

  2001influential reference
• Allergic diathesis in transgenic mice with constitutive T cell expression of inducible vasoactive intestinal peptide receptor

  2001cited by this paper
• Cutting Edge: Is Vasoactive Intestinal Peptide a Type 2 Cytokine?

  2001cited by this paper
• Vasoactive Intestinal Peptide Mediation of Development and Functions of T Lymphocytes

  2000cited by this paper
• The neuropeptides VIP and PACAP inhibit IL-2 transcription by decreasing c-Jun and increasing JunB expression in T cells.

  2000influential reference
• Differential Activation of Phospholipase D by VPAC and PAC1 Receptors

  2000cited by this paper
• Vipergic innervation of the mammalian pineal gland

  1999cited by this paper
• Vasoactive Intestinal Peptide and Pituitary Adenylate Cyclase-activating Polypeptide Inhibit Interleukin-12 Transcription by Regulating Nuclear Factor κB and Ets Activation*

  1999cited by this paper
• Selectivity of Effects of Vasoactive Intestinal Peptide on Macrophages and Lymphocytes in Compartmental Immune Responses a

  1998cited by this paper
• Role of VIP, PACAP, and related peptides in the regulation of the hypothalamo-pituitary-adrenal axis.

  1998cited by this paper
• Vasoactive intestinal peptide modulates T lymphocyte migration in Peyer's patches of rat small intestine.

  1997cited by this paper
• Discovery of a Novel, Potent, and Src Family-selective Tyrosine Kinase Inhibitor

  1996cited by this paper
• Down‐regulation of Cytokine Expression in Murine Lymphocytes by PACAP and VIP

  1996cited by this paper
• Differential expression of vasoactive intestinal peptide receptors 1 and 2 (VIP-R1 and VIP-R2) mRNA in murine lymphocytes.

  1996cited by this paper
• Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide-38 inhibit IL-10 production in murine T lymphocytes.

  1996cited by this paper
• Pituitary adenylate cyclase activating polypeptide (PACAP) and vasoactive intestinal peptide stimulate two signaling pathways in CHO cells stably transfected with the selective type I PACAP receptor

  1995cited by this paper
• Neuropeptide signaling of lymphocytes in immunological responses.

  1995cited by this paper
• Human T lymphocyte chemotaxis and adhesion induced by vasoactive intestinal peptide.

  1994cited by this paper
• Vasoactive intestinal peptide inhibits interleukin (IL)-2 and IL-4 production through different molecular mechanisms in T cells activated via the T cell receptor/CD3 complex.

  1993cited by this paper
• Murine mucosal T cells have VIP receptors functionally distinct from those on intestinal epithelial cells.

  1992cited by this paper
• Vasoactive intestinal peptide-containing nerves in Peyer's patches.

  1987cited by this paper
• Noradrenergic Sympathetic Neural Interactions with the Immune System: Structure and Function

  1987cited by this paper
• In vitro alteration of receptors for vasoactive intestinal peptide changes the in vivo localization of mouse T cells

  1984cited by this paper
• Interaction of vasoactive intestinal peptide with mouse lymphocytes: specific binding and the modulation of mitogen responses.

  1984cited by this paper
• Direct activation of calcium-activated, phospholipid-dependent protein kinase by tumor-promoting phorbol esters.

  1982cited by this paper
• Vasoactive intestinal polypeptide modulation of lymphocyte adenylate cyclase.

  1981cited by this paper
• Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4

  1970cited by this paper
• The FASEB Journal express article 10.1096/fj.02-0248fje. Published online August 21, 2002.

  year unknowncited by this paper

• Human CD4+CD45RA+ T Cells Behavior after In Vitro Activation: Modulatory Role of Vasoactive Intestinal Peptide

  2022cites this paper
• Messenger RNA Gene Expression Screening of VIP and PACAP Neuropeptides and Their Endogenous Receptors in Ruminants

  2022cites this paper
• iLluminate-miRNA: Paradigm for high-throughput, low-cost, and sensitive miRNA detection in serum samples at point-of-care

  2018cites this paper
• VPAC1 receptor (Vipr1)-deficient mice exhibit ameliorated experimental autoimmune encephalomyelitis, with specific deficits in the effector stage

  2016cites this paper
• VIP and PACAP as Regulators of Immunity: New Perspectives from A Receptor Point of View

  2016cites this paper
• Efecto del péptido intestinal vasoactivo sobre los linfocitos Th17 y su relación con otras subpoblaciones th: implicación en enfermedades autoinmunes-inflamatorias

  2016cites this paper
• Th17 polarization of memory Th cells in early arthritis: the vasoactive intestinal peptide effect

  2015cites this paper
• Characterization and use of a rabbit-anti-mouse VPAC1 antibody by flow cytometry.

  2012cites this paper
• Biological effects of vasoactive intestinal peptide/pituitary adenylate cyclase activating polypeptide receptor 1 (VPAC1) and VPAC2 on chemotaxis and its regulation of the tumor suppressor Ikaros in leukemic T cells

  2012influential citation
• Targeting VIP and PACAP receptor signalling: new therapeutic strategies in multiple sclerosis

  2011cites this paper
• Radical reversal of vasoactive intestinal peptide (VIP) receptors during early lymphopoiesis.

  2011cites this paper
• Vasoactive intestinal peptide receptor 1 is downregulated during expansion of antigen-specific CD8 T cells following primary and secondary Listeria monocytogenes infections.

  2011influential citation
• Vasoactive intestinal peptide signaling axis in human leukemia.

  2011cites this paper
• Identification of the early VIP-regulated transcriptome and its associated, interactome in resting and activated murine CD4 T cells.

  2010influential citation
• A transcriptionally permissive epigenetic landscape at the vasoactive intestinal peptide receptor-1 promoter suggests a euchromatin nuclear position in murine CD4 T cells.

  2009influential citation
• Stimulatory and suppressive signal transduction regulates vasoactive intestinal peptide receptor-1 (VPAC-1) in primary mouse CD4 T cells.

  2008cites this paper
• Anti-inflammatory neuropeptides: a new class of endogenous immunoregulatory agents.

  2008cites this paper